Review
Cardiac & Cardiovascular Systems
Claire Tonry, Adam Russell-Hallinan, Claire McCune, Patrick Collier, Mark Harbinson, Lana Dixon, Chris J. Watson
Summary: Cancer therapeutics-related cardiac dysfunction (CTRCD) is a major cause of disease and death in cancer survivors. The clinical management of CTRCD is hindered by a lack of sensitive diagnostic and prognostic strategies. Circulating molecular markers could potentially be useful in the diagnosis and management of CTRCD. Researchers have been searching for new biomarkers and hope that these markers can also guide the development of cardio-protective therapies.
CARDIOVASCULAR RESEARCH
(2023)
Review
Cardiac & Cardiovascular Systems
Gillian Murtagh, James L. Januzzi, Marielle Scherrer-Crosbie, Tomas G. Neilan, Susan Dent, Jennifer E. Ho, Vinesh Appadurai, Ray McDermott, Nausheen Akhter
Summary: Cardiotoxicity is a growing concern in the oncology population. Current imaging techniques for surveillance are relatively insensitive and resource intensive, highlighting the need for more sensitive and cost-effective strategies. Circulating cardiovascular biomarkers offer a promising solution, but there are limitations to their use. This review discusses the challenges in biomarker measurement and interpretation, and suggests improved study designs and harmonization efforts to enhance their predictive value.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Review
Cardiac & Cardiovascular Systems
Wanli Sun, Juping Xu, Li Wang, Yuchen Jiang, Jingrun Cui, Xin Su, Fan Yang, Li Tian, Zeyu Si, Yanwei Xing
Summary: ncRNAs play a crucial role in cancer therapy-induced cardiotoxicity and are closely related to its mechanisms and disease progression. They have the potential to be used for early detection and improvement of treatment outcomes.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Sneha S. S. Pillai, Duane G. G. Pereira, Gloria Bonsu, Hibba Chaudhry, Nitin Puri, Hari Vishal Lakhani, Maria Tria Tirona, Komal Sodhi, Ellen Thompson
Summary: This study aims to develop a panel of novel biomarkers and circulating miRNAs for early screening of trastuzumab-induced cardiotoxicity in breast cancer patients. The results showed significant upregulation of biomarkers and circulating miRNAs specific to cardiac injury and remodeling at 3- and 6-months post trastuzumab therapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Fei Fei Gong, Gregory J. Cascino, Gillian Murtagh, Nausheen Akhter
Summary: This review explores the evidence for circulating biomarkers in cardiotoxicity prediction associated with cancer therapies, with troponins and natriuretic peptides having the broadest evidence base for risk prediction.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
ZiYan Yang, Wei Wang, Xiaojia Wang, ZhiQuan Qin
Summary: Breast cancer is the most common form of cancer in women and HER2 overexpression is responsible for a percentage of cases. HER2-targeted therapy has improved survival rates, but concerns about cardiotoxicity remain, with possible mechanisms linked to mitochondrial ROS increase and cell apoptosis. Monitoring NT-proBNP levels may aid in predicting and managing this cardiotoxicity.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jyotsnamayee Nayak, P. Seshu Vardhan, Suban K. Sahoo, Manish Kumar, Vinod Kumar Vashistha, Rajender Kumar
Summary: Doxorubicin is an effective antineoplastic agent, but it has serious side effects on the heart. Nutritionists recommend using antioxidants to alleviate these side effects during chemotherapy, but this recommendation is not supported by oncologists. In this study, in silico pharmacokinetics and combination effects of Doxorubicin and antioxidants were explored on therapeutic targets involved in cancer proliferation and post-myocardial infarction.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Review
Cardiac & Cardiovascular Systems
Irene Cartas-Espinel, Marcelino Telechea-Fernandez, Carlos Manterola Delgado, Andres Avila Barrera, Nicolas Saavedra Cuevas, Angela L. Riffo-Campos
Summary: This scoping review aimed to identify novel molecular biomarkers associated with cardiotoxicity in cancer patients. A total of 42 eligible studies were included, and data were extracted for 272 novel molecular biomarkers. Only 13 biomarkers were identified as promising predictors in more than one study.
Review
Oncology
Valeria Cantoni, Roberta Green, Roberta Assante, Adriana D'Antonio, Francesca Maio, Emanuele Criscuolo, Roberto Bologna, Mario Petretta, Alberto Cuocolo, Wanda Acampa
Summary: A scoping review was conducted to summarize the prevalence of cardiotoxicity evaluated by noninvasive imaging procedures in cancer patients. The summary prevalence of CTRCD was found to be 17% based on the reviewed studies.
Review
Medicine, General & Internal
Kondylia Antoniadi, Nikolaos Thomaidis, Petros Nihoyannopoulos, Konstantinos Toutouzas, Evangelos Gikas, Charikleia Kelaidi, Sophia Polychronopoulou
Summary: Improvements in the treatment of childhood cancer have increased survival rates, but also led to the occurrence of cardiotoxicity. This article reviews the definition, diagnosis methods, and new technologies in the field of cardio-oncology. Omics science offers new opportunities for biomarker discovery and understanding the mechanisms of cardiotoxicity.
Article
Cardiac & Cardiovascular Systems
Yuri Kim, Jonathan G. Seidman, Christine E. Seidman
Summary: With the increase in the number of cancer survivors, the side effects of cancer therapies are becoming more recognized. Genetics play a substantial role in susceptibility to cardiovascular toxicities from cancer therapies, in addition to traditional cardiovascular risk factors.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Carmine Rocca, Ernestina Marianna De Francesco, Teresa Pasqua, Maria Concetta Granieri, Anna De Bartolo, Maria Eugenia Gallo Cantafio, Maria Grazia Muoio, Massimo Gentile, Antonino Neri, Tommaso Angelone, Giuseppe Viglietto, Nicola Amodio
Summary: Mitochondria play a crucial role in maintaining myocardial tissue homeostasis and their impairments can lead to cardiovascular diseases. Anti-cancer drugs can induce mitochondrial toxicity, resulting in cell death.
Article
Cardiac & Cardiovascular Systems
Anand Rohatgi, Marit Westerterp, Arnold von Eckardstein, Alan Remaley, Kerry-Anne Rye
Summary: Low high-density lipoprotein cholesterol (HDL-C) is associated with adverse lifestyle choices, cardiovascular diseases, inflammatory disorders, and other conditions. Therapeutic strategies targeting HDL-C levels have not been successful, and future focus should be on optimizing HDL function for better outcomes.
Review
Oncology
Theodorus W. Kouwenberg, Elvira C. van Dalen, Elizabeth A. M. Feijen, Stejara A. Netea, Melissa Bolier, Martijn G. Slieker, Firdaus A. A. Mohamed Hoesein, Leontien C. M. Kremer, Heynric B. Grotenhuis, Annelies M. C. Mavinkurve-Groothuis
Summary: This systematic review discusses the prevalence and risk factors for acute and early-onset cardiotoxicity in children and adolescents with cancer treated with anthracyclines, mitoxantrone or radiotherapy involving the heart. The study found that the definitions of cardiotoxicity varied significantly among studies, making it difficult to establish the exact prevalence. Cumulative anthracycline dose was identified as an important risk factor. The findings highlight the importance of establishing uniform international guidelines for monitoring cardiac function during and shortly after childhood cancer treatment.
Review
Cardiac & Cardiovascular Systems
Yihua Liu, Li Zheng, Xingjuan Cai, Xiaojun Zhang, Yang Ye
Summary: Cancer treatment has shifted from non-specific cytotoxic agents to molecularly targeted drugs. However, the use of targeted drugs in breast cancer patients has led to an increasing rate of deaths due to non-tumor-related causes, with cardiovascular complications as the most common cause. This article reviews the occurrence, mechanisms, monitoring methods, and progress in the prevention and treatment of cardiotoxicity associated with targeted therapy for breast cancer.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)